Corpus overview


Overview

MeSH Disease

Human Phenotype

Transmission

Seroprevalence
    displaying 1 - 4 records in total 4
    records per page




    Necrotising Vasculitis MESHD Vasculitis HP in Covid-19: watch out for bowel perforation

    Authors: Tonia Persiano; Francesca Grulli; Pietro Cornara; Francesca Bonomi; Alberto Casazza; Anna Coci; Sabina Teresa Mediani; Elisabetta Bellazzi; Livio Carnevale

    doi:10.21203/rs.3.rs-79258/v1 Date: 2020-09-17 Source: ResearchSquare

    Introduction: SARS-Cov-2 infection can be asymptomatic TRANS, greatly impair respiratory function and, sometimes, affect other organs. Gastro-enteric involvement seems to be not so rare and many patients suffered for abdominal pain HP abdominal pain MESHD, anorexia HP anorexia MESHD, nausea and vomiting HP nausea and vomiting MESHD vomiting MESHD, diarrhoea MESHD or jaundice HP jaundice MESHD. Case presentation: Here we report a case of a Covid-19 patient who developed a right colon perforation HP colon perforation MESHD due to a pseudomembranous colitis MESHD colitis without Clostridium Difficile HP toxins finding associated to a necrotising vasculitis MESHD vasculitis HP. In this patient a PCR test performed on gastric fluid showed SARS-CoV-2 enteric replication. Discussion: Necrotizing vasculitis MESHD vasculitis HP is an anatomopathological typical findings in Covid-19. It has been documented in several organs and tissues. In our case, evident foci of necrotizing vasculitis MESHD vasculitis HP with intravascular obliteration by fibrin thrombi with macrophagic cells infiltration are anatomopathological findings of a CD toxins free pseudomembranous colitis MESHD colitis HP leading to bowel perforation. Conclusions: Bowel perforation due to necrotizing vasculitis MESHD vasculitis HP leading to pseudomembranous colitis MESHD colitis HP could be a SARS-Cov-2 related clinical finding.

    Clinical characteristics of neonates with coronavirus disease MESHD 2019 (COVID-19): a systematic review

    Authors: Yuan Hu; Jing Xiong; Yuan Shi

    doi:10.21203/rs.3.rs-50795/v1 Date: 2020-07-29 Source: ResearchSquare

    This study aimed to summarize the existing literature on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection MESHD in newborns to clarify the clinical features and outcomes of neonates with COVID-19. A systematic search was performed in PubMed, Embase, Cochrane Library, China National Knowledge Infrastructure (CNKI), Wanfang Data, and VIP databases from January 1, 2019 to April 30, 2020. The references of relevant studies were also searched. A descriptive summary was organized by aspects of clinical presentations (symptoms, laboratory examinations, and imaging) and outcomes. We identified 14 studies reporting 18 newborns with COVID-19. The most common clinical manifestations were fever HP fever MESHD (62.5%), shortness of breath MESHD (50.0%), diarrhea HP diarrhea MESHD/ vomiting HP vomiting MESHD/feeding intolerance(43.8%), cough HP (37.5%), dyspnea HP dyspnea MESHD (25.0%), and nasal congestion/runny nose/ sneeze HP(25.0%). Atypical symptoms included jaundice HP jaundice MESHD and convulsion MESHD. Lymphocyte numbers decreased in 5 cases, and radiographic findings were likely to show pneumonia HP pneumonia MESHD. All newborns recovered and discharged from the hospital, and there was no death.Conclusion: Clinical symptoms of neonatal SARS-CoV-2 infection MESHD are atypical, most of them are mild. Up to now, the prognosis of newborns is good, and there is no death. Intrauterine vertical transmission TRANS is possible, but confirmed evidence is still lacking. The Long-term follow-up of potential influences of SARS-CoV-2 infection MESHD on neonates need further exploration.

    Inflammation MESHD and Endothelial Injury Profiling in COVID-19 Pediatric Multi-system Inflammatory Syndrome MESHD

    Authors: Douglas Fraser; Eric Patterson; Mark Daley; Gedaminas Cepinskas

    doi:10.21203/rs.3.rs-33772/v1 Date: 2020-06-05 Source: ResearchSquare

    Background COVID-19 is associated with a novel multi-system inflammatory syndrome MESHD that shares some characteristics with Kawasaki’s Disease MESHD. The syndrome manifestation is delayed relative to COVID-19 onset, with a spectrum of clinical severity. Clinical signs may include persistent fever HP fever MESHD, gastrointestinal symptoms MESHD, cardiac inflammation MESHD and/or shock HP.Case Presentation: We measured 59 inflammatory and endothelial injury plasma SERO analytes in an adolescent girl that presented with malaise, fever HP fever MESHD, cough HP cough MESHD, strawberry tongue HP and jaundice HP jaundice MESHD. Her COVID-19 status was positive with detection of 2 SARS-CoV-2 viral genes using polymerase chain reaction. She was treated with intravenous immunoglobulin prior to blood SERO draw, but our plasma SERO measurements suggested a unique analyte expression pattern associated with inflammation MESHD, endothelial injury MESHD and microvascular glycocalyx degradation.Conclusions COVID-19 is associated with a multi-system inflammatory syndrome MESHD and a unique inflammatory and endothelial injury signature. Analyte markers of inflammation MESHD and endothelium injury might serve as putative biomarkers and/or be investigated further as potential therapeutic targets.

    In Silico Investigation of Phytoconstituents from Indian Medicinal Herb 'Tinospora cordifolia (Giloy)' against SARS-CoV-2 (COVID-19) by Molecular Dynamics Approach

    Authors: Papia Chowdhury

    id:2007.00621v2 Date: 2020-05-29 Source: arXiv

    The recent appearance of COVID-19 virus has created a global crisis due to unavailability of any vaccine or drug that can effectively and deterministically work against it. Naturally, different possibilities (including herbal medicines having known therapeutic significance) have been explored by the scientists. The systematic scientific study (beginning with in silico study) of herbal medicines in particular and any drug in general is now possible as the structural components (proteins) of COVID-19 are already characterized. The main protease of COVID-19 virus is $\rm{M^{pro}}$ or $\rm{3CL^{pro}}$ which is a key CoV enzyme and an attractive drug target as it plays a pivotal role in mediating viral replication and transcription. In the present study, $\rm{3CL^{pro}}$ is used to study drug:3CLpro interactions and thus to investigate whether all or any of the main chemical constituents of Tinospora cordifolia (e.g., berberine $\rm{(C_{20}H_{18}NO_{4})}$, $\beta$-sitosterol $\rm{(C_{29}H_{50}O)}$, choline $\rm{(C_{5}H_{14}NO)}$, tetrahydropalmatine $\rm{(C_{21}H_{25}NO_{4})}$ and octacosanol $\rm{(C_{28}H_{58}O))}$ can be used as an anti-viral drug against SARS-CoV-2. The in silico study performed using tools of network pharmacology, molecular docking including molecular dynamics have revealed that among all considered phytochemicals in Tinospora cordifolia, berberine can regulate $\rm{3CL^{pro}}$ protein's function due to its easy inhibition and thus can control viral replication. The selection of Tinospora cordifolia was motivated by the fact that the main constituents of it are known to be responsible for various antiviral activities and the treatment of jaundice HP jaundice MESHD, rheumatism MESHD, diabetes MESHD, etc.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from Preprints.org and is updated on a daily basis (7am CET/CEST).
The web page can also be accessed via API.

Sources


Annotations

All
None
MeSH Disease
Human Phenotype
Transmission
Seroprevalence


Export subcorpus as...

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.